Literature search services are currently unavailable. During our hosting provider's UPS upgrade we experienced a hardware failure and are currently working to resolve the issue.

Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β.

Mutations in sarcomere protein genes can cause hypertrophic cardiomyopathy (HCM), a disorder characterized by myocyte enlargement, fibrosis, and impaired ventricular relaxation. Here, we demonstrate that sarcomere protein gene mutations activate proliferative and profibrotic signals in non-myocyte cells to produce pathologic remodeling in HCM. Gene expression analyses of non-myocyte cells isolated from HCM mouse hearts showed increased levels of RNAs encoding cell-cycle proteins, Tgf-β, periostin, and other profibrotic proteins. Markedly increased BrdU labeling, Ki67 antigen expression, and periostin immunohistochemistry in the fibrotic regions of HCM hearts confirmed the transcriptional profiling data. Genetic ablation of periostin in HCM mice reduced but did not extinguish non-myocyte proliferation and fibrosis. In contrast, administration of Tgf-β-neutralizing antibodies abrogated non-myocyte proliferation and fibrosis. Chronic administration of the angiotensin II type 1 receptor antagonist losartan to mutation-positive, hypertrophy-negative (prehypertrophic) mice prevented the emergence of hypertrophy, non-myocyte proliferation, and fibrosis. Losartan treatment did not reverse pathologic remodeling of established HCM but did reduce non-myocyte proliferation. These data define non-myocyte activation of Tgf-β signaling as a pivotal mechanism for increased fibrosis in HCM and a potentially important factor contributing to diastolic dysfunction and heart failure. Preemptive pharmacologic inhibition of Tgf-β signals warrants study in human patients with sarcomere gene mutations.

Pubmed ID: 20811150


  • Teekakirikul P
  • Eminaga S
  • Toka O
  • Alcalai R
  • Wang L
  • Wakimoto H
  • Nayor M
  • Konno T
  • Gorham JM
  • Wolf CM
  • Kim JB
  • Schmitt JP
  • Molkentin JD
  • Norris RA
  • Tager AM
  • Hoffman SR
  • Markwald RR
  • Seidman CE
  • Seidman JG


The Journal of clinical investigation

Publication Data

October 8, 2010

Associated Grants

  • Agency: NCRR NIH HHS, Id: C06 RR018823
  • Agency: NHLBI NIH HHS, Id: HL33756
  • Agency: NCRR NIH HHS, Id: P20RR016434
  • Agency: NCRR NIH HHS, Id: P20RR021949
  • Agency: Howard Hughes Medical Institute, Id:

Mesh Terms

  • Animals
  • Bromodeoxyuridine
  • Cardiomyopathy, Hypertrophic
  • Cell Proliferation
  • Disease Models, Animal
  • Fibrosis
  • Losartan
  • Mice
  • Mutation
  • Myocardium
  • Myocytes, Cardiac
  • Sarcomeres
  • Signal Transduction
  • Transforming Growth Factor beta